Business Wire

NY-ALVAREZ-&-MARSAL

Share
Alvarez & Marsal Expands Its Capital Markets & Accounting Advisory Senior Talent Globally

Leading global professional services firm Alvarez & Marsal (A&M) announced the appointment of Stockholm-based Annika Melin Jakobsson and New York-based Patricia Alonso de la Fuente as Global Transaction Advisory Group (TAG) Managing Directors within its Capital Markets & Accounting Advisory (CMAA) practice. Ms. Melin Jakobsson will develop A&M’s CMAA offering in the Nordics and EMEA. Ms. Alonso de la Fuente will support CMAA in the US, Spain and its continued Latin American (LatAm) expansion.

Paul Aversano, Global Practice Leader of A&M’s Global Transaction Advisory Group, said, “Building our CMAA offering in the Nordics and EMEA while expanding it across LatAm and Spanish speaking countries enhances our independent capital markets and advisory accounting advice capabilities for private equity (PE) and multinational corporate clients seeking transaction support. Following on CMAA Managing Director Ayres Moura’s recent hire, Annika’s and Patricia’s joining aligns with our strategic talent, capabilities, and geographic growth plan.”

Ms. Melin Jakobsson, A&M’s Nordic CMAA practice Leader who will support this offering across EMEA, specializes in initial public offerings (IPO), carve-outs, capital markets transactions, corporate governance, risk, compliance, and all mergers and acquisitions (M&A) lifecycle aspects. She advises board and management teams, in listed and non-listed companies, and has led national and international large- mid- and small cap IPOs and capital markets transactions. Ms. Melin Jakobsson ensures clients’ IPO readiness, and once listed, their alignment with capital markets’ governance, risk and compliance and financial reporting requirements.

Ms. Alonso de la Fuente’s global mindset and local expertise crisscrosses her extensive cross-border and cross-functional market transaction experience. She focuses on IPOs, acquisitions, divestitures, international financial reporting standards (IFRS), US generally accepted accounting principles (GAAP) conversions and complex technical accounting matters. Additionally, she has led complex, cross-functional M&A and IPO projects and developed holistic solutions for clients across diverse sectors in the Americas and Europe.

Phil Mitchell, EMEA TAG Practice Co-Leader, noted, “A&M’s freedom from audit conflicts and integrated platform enables independent capital markets and accounting advice that maximizes value for PE and corporate clients. Annika’s and Patricia’s combined expertise solidifies our global CMAA offering and elevates our exit readiness capabilities.”

Previously, Ms. Melin Jakobsson served as Managing Partner for EY’s Nordic Capital Markets group and Managing Partner for KPMG’s Deal Advisory Capital Markets Group in Sweden. While at KPMG, she also served as a member of its board of directors.

Prior to joining A&M, Ms. Alonso de la Fuente served with KPMG, most recently as Partner in Deal Advisory in New York, along with leading that firm’s Capital Markets and Accounting Advisory Services US-LatAm corridor.

Mses. Melin Jakobsson and Alonso de la Fuente, said, “Capital markets are part of the transaction lifecycle. With tailored teams to meet needs and demands, A&M’s business model supports clients wherever we are in that cycle. Across the transaction spectrum, from aligning IPO readiness to planning exits, now is the time for corporates and PE to prepare.”

Ms. Melin Jakobsson earned a master’s degree in law from Uppsala University and has been part of the Swedish Nasdaq Listing Auditor’s team for 10+ years. She has been engaged as a capital market specialist by the Swedish Institute for the Accountancy Profession, Accountancy Europe and the Centre for Business and Policy Studies.

Ms. Alonso de la Fuente holds a bachelor’s degree in business administration from Complutense University, Madrid, and Leeds, United Kingdom.

About Alvarez & Marsal

Companies, investors and government entities around the world turn to Alvarez & Marsal (A&M) for leadership, action and results. Privately held since its founding in 1983, A&M is a leading global professional services firm that provides advisory, business performance improvement and turnaround management services. When conventional approaches are not enough to create transformation and drive change, clients seek our deep expertise and ability to deliver practical solutions to their unique problems.

With over 9,000 people across six continents, we deliver tangible results for corporates, boards, private equity firms, law firms and government agencies facing complex challenges. Our senior leaders, and their teams, leverage A&M’s restructuring heritage to help companies act decisively, catapult growth and accelerate results. We are experienced operators, world-class consultants, former regulators and industry authorities with a shared commitment to telling clients what is really needed for turning change into a strategic business asset, managing risk and unlocking value at every stage of growth.

About Alvarez & Marsal Global Transaction Advisory Group

A&M’s Global Transaction Advisory Group provides investors and lenders the answers needed to get the deal done. We combine our firm’s deep operational, industry and functional resources with Big Four-quality financial accounting and tax expertise to assess key deal drivers and focus on the root cause of any critical deal issues. As the largest transaction advisory practice outside the Big Four, our global integrated teams help private equity, sovereign wealth funds, family offices and hedge funds as well as corporate acquirers unlock value across the investment lifecycle.

The firm’s Global Transaction Advisory Group includes over 950 professionals in 37 offices worldwide. Our global team has extensive industry knowledge across multiple sectors and is free from audit-based conflicts of interests.

To learn more, visit: AlvarezandMarsal.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240122439270/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye